Kymera TherapeuticsNASDAQ: KYMR

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024

Kymera (KYMR) announced a smaller loss than anticipated for the first quarter. The company anticipates that its current cash reserves will last until the first half of 2027.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) Q1 2024 Earnings Conference Call on May 2, 2024 at 8:30 AM ET. Company representatives include Justine Koenigsberg, Nello Mainolfi, Jared Gollob, and Bruce Jacobs. Various analysts from firms like Stifel Nicolaus, J.P. Morgan, and Wolfe Research also participated in the conference call. The Operator welcomed all participants to the Kymera Therapeutics First Quarter 2024 Results Conference Call.

Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.

Kymera's KT-474 shows promise in Phase I for HS and AD, balancing clinical potential with financial challenges. Despite revenue decrease, Kymera's strong current ratio and ample cash reserves provide short-term financial stability. Market sentiment is mixed, with high short interest and cautious institutional and insider activities reflecting investor skepticism.

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Bruce Jacobs - CFO Conference Call Participants Brad Canino - Stifel Gospel M. Enyindah-Asonye - Morgan Stanley Marc Frahm - TD Cowen Eric Joseph - JPMorgan Srikripa Devarakonda - Truist Securities Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Kalpit Patel - B.

Kymera Therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.